CYCC
Price
$7.95
Change
-$0.94 (-10.57%)
Updated
Aug 15 closing price
Capitalization
12.63M
ICCC
Price
$6.10
Change
-$0.62 (-9.23%)
Updated
Aug 15 closing price
Capitalization
55.16M
Interact to see
Advertisement

CYCC vs ICCC

Header iconCYCC vs ICCC Comparison
Open Charts CYCC vs ICCCBanner chart's image
Cyclacel Pharmaceuticals
Price$7.95
Change-$0.94 (-10.57%)
Volume$208K
Capitalization12.63M
ImmuCell
Price$6.10
Change-$0.62 (-9.23%)
Volume$32.97K
Capitalization55.16M
CYCC vs ICCC Comparison Chart in %
Loading...
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYCC vs. ICCC commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYCC is a Hold and ICCC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (CYCC: $7.95 vs. ICCC: $6.10)
Brand notoriety: CYCC and ICCC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYCC: 6% vs. ICCC: 126%
Market capitalization -- CYCC: $12.63M vs. ICCC: $55.16M
CYCC [@Biotechnology] is valued at $12.63M. ICCC’s [@Biotechnology] market capitalization is $55.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYCC’s FA Score shows that 0 FA rating(s) are green whileICCC’s FA Score has 0 green FA rating(s).

  • CYCC’s FA Score: 0 green, 5 red.
  • ICCC’s FA Score: 0 green, 5 red.
According to our system of comparison, ICCC is a better buy in the long-term than CYCC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYCC’s TA Score shows that 5 TA indicator(s) are bullish while ICCC’s TA Score has 4 bullish TA indicator(s).

  • CYCC’s TA Score: 5 bullish, 5 bearish.
  • ICCC’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CYCC and ICCC are a good buy in the short-term.

Price Growth

CYCC (@Biotechnology) experienced а -9.45% price change this week, while ICCC (@Biotechnology) price change was -8.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ICCC($55.2M) has a higher market cap than CYCC($12.6M). ICCC has higher P/E ratio than CYCC: ICCC (29.06) vs CYCC (0.00). ICCC YTD gains are higher at: 18.505 vs. CYCC (-91.190). ICCC has higher annual earnings (EBITDA): 2.94M vs. CYCC (-12.68M). ICCC has more cash in the bank: 4.6M vs. CYCC (93K). CYCC has less debt than ICCC: CYCC (9K) vs ICCC (14.7M). ICCC has higher revenues than CYCC: ICCC (27.3M) vs CYCC (14K).
CYCCICCCCYCC / ICCC
Capitalization12.6M55.2M23%
EBITDA-12.68M2.94M-431%
Gain YTD-91.19018.505-493%
P/E Ratio0.0029.060%
Revenue14K27.3M0%
Total Cash93K4.6M2%
Total Debt9K14.7M0%
FUNDAMENTALS RATINGS
CYCC vs ICCC: Fundamental Ratings
CYCC
ICCC
OUTLOOK RATING
1..100
9775
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
10098
SMR RATING
1..100
10090
PRICE GROWTH RATING
1..100
9745
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
4050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ICCC's Valuation (77) in the Medical Specialties industry is in the same range as CYCC (84) in the Biotechnology industry. This means that ICCC’s stock grew similarly to CYCC’s over the last 12 months.

ICCC's Profit vs Risk Rating (98) in the Medical Specialties industry is in the same range as CYCC (100) in the Biotechnology industry. This means that ICCC’s stock grew similarly to CYCC’s over the last 12 months.

ICCC's SMR Rating (90) in the Medical Specialties industry is in the same range as CYCC (100) in the Biotechnology industry. This means that ICCC’s stock grew similarly to CYCC’s over the last 12 months.

ICCC's Price Growth Rating (45) in the Medical Specialties industry is somewhat better than the same rating for CYCC (97) in the Biotechnology industry. This means that ICCC’s stock grew somewhat faster than CYCC’s over the last 12 months.

ICCC's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as CYCC (100) in the Biotechnology industry. This means that ICCC’s stock grew similarly to CYCC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYCCICCC
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 25 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 4 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CYCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GRCAF0.080.01
+15.30%
GOLD SPRINGS RESOURCE CORP.
MLSPF8.370.28
+3.50%
Melrose Industries PLC
FDMDF0.29N/A
N/A
4DMEDICAL LTD
BCEPF13.59N/A
N/A
BCE Inc.
TVAVF22.70-1.23
-5.16%
Tel Aviv Stock Exchange Ltd.

CYCC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCC has been loosely correlated with MIRM. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCC jumps, then MIRM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCC
1D Price
Change %
CYCC100%
-10.57%
MIRM - CYCC
36%
Loosely correlated
+4.78%
ORMP - CYCC
30%
Poorly correlated
-1.89%
IMMP - CYCC
27%
Poorly correlated
+0.58%
RNAC - CYCC
26%
Poorly correlated
-0.87%
ICCC - CYCC
26%
Poorly correlated
-9.18%
More

ICCC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ICCC has been loosely correlated with NKTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ICCC jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICCC
1D Price
Change %
ICCC100%
-9.18%
NKTX - ICCC
43%
Loosely correlated
+5.91%
BOLT - ICCC
26%
Poorly correlated
-5.33%
JANX - ICCC
24%
Poorly correlated
+0.56%
NERV - ICCC
24%
Poorly correlated
+25.35%
IMMP - ICCC
23%
Poorly correlated
+0.58%
More